Peels
5 min readLayering Peels With Polynucleotides for Recovery
Educational reading for licensed practitioners — not clinical or injection guidance.
Resurfacing and regeneration solve different problems. A peel removes damaged surface layers and triggers a controlled wound-healing response; polynucleotides work deeper, supporting fibroblast activity, hydration and tissue repair. Used thoughtfully in sequence, the two can complement each other — the peel refines tone and texture while the regenerative step shortens and smooths the recovery. Used carelessly, they simply stack inflammation. The difference is entirely in the timing.
Why the pairing makes sense
Polynucleotides are fragments of purified DNA, most often of marine origin, that act as a scaffold and signalling support for repair. Injectable ranges such as Plinest, Newest, Polyphil and Croma Philart are used internationally to improve skin quality, hydration and elasticity. It is worth stating plainly for compliance: no injectable polynucleotide or PDRN product, including Rejuran, holds FDA approval; these are CE-marked devices used widely outside the United States.
A peel, meanwhile, deliberately provokes a healing cascade in the epidermis and upper dermis. Feeding that cascade with a regenerative stimulus is logical — provided the skin barrier has recovered enough to be needled safely.
Sequencing: peel first, then regenerate
The reliable order is peel first, polynucleotides once the barrier has settled. Injecting into skin that is still shedding, inflamed or compromised raises the risk of irregular results and prolonged redness, and it makes any adverse reaction harder to interpret.
A workable framework:
- Superficial peel — mandelic, lactic or salicylic, or a buffered TCA system such as PRX-T33 or WiQo PRX-T33, which cause little to no open downtime.
- Recovery window — allow the acute phase to resolve. For a light peel that is often a matter of days; for anything with visible flaking, wait until the surface is intact.
- Polynucleotide session — proceed once the skin is calm, then space subsequent regenerative sessions on their own schedule.
For a formulation that already sits at the surface, BioRePeel is popular precisely because its two-phase design limits frosting and downtime, which shortens the gap before a regenerative step becomes appropriate.
Do not treat on the same needle pass
Peeling and injecting in a single visit is tempting for scheduling, but it compresses two inflammatory events into one and removes your ability to tell which step caused a problem. Separating them also lets the patient consent to each stage on its own merits. If a same-day protocol is unavoidable, keep the peel superficial and the injection conservative, and document the decision.
Supporting the skin between steps
Topicals bridge the two procedures and protect the investment. A regenerative post-treatment cream such as Mastelli Turnover Cream with polynucleotides suits the recovery window, while barrier-focused options keep the skin comfortable and reduce the chance of PIH. Strict daily broad-spectrum SPF is non-negotiable across the whole protocol — the pigment risk from a peel does not end when the redness does.
Who benefits most
This pairing earns its place in patients who want more than surface refinement: dull, dehydrated or early-ageing skin, under-eye crepiness, and those recovering skin quality after a period of neglect or sun damage. It is less suited to patients with active infection, a compromised barrier, or unrealistic expectations of a single visit. As always, screen for pregnancy, active acne flares and recent isotretinoin use before either step.
The Takeaway
Think of the peel and the polynucleotide course as two phases of one plan rather than two products sold together. Peel first, let the barrier recover, then regenerate — and never compress both into a single inflamed session. Sequenced this way, the resurfacing step and the repair step reinforce each other, and the recovery is calmer than either would be alone.
Browse the polynucleotide injections range to plan the regenerative half of the protocol.